<?xml version='1.0' encoding='utf-8'?>
<document id="30314487"><sentence text="Potential drug-drug interactions in outpatient department of a tertiary care hospital in Pakistan: a cross-sectional study." /><sentence text="Potential drug-drug interactions (pDDIs) are one of the preventable drug related problems having the risk of serious adverse events or therapeutic failure" /><sentence text=" In developing countries like Pakistan, this issue remains poorly addressed" /><sentence text=" The objective of this study was to explore prevalence of pDDIs in the Outpatient Department (OPD) of a tertiary care hospital in Pakistan" /><sentence text=" The secondary aim was to describe the levels of reported pDDIs and develop a list of widespread clinically relevant interactions" /><sentence text="" /><sentence text="Prescriptions of 2400 OPD patients were analyzed for pDDIs through Micromedex Drug-Reax®" /><sentence text=" Prevalence, severity- and documentation-levels and widespread clinically relevant interactions were reported" /><sentence text="" /><sentence text="Of total 2400 prescriptions, pDDIs were present in 22" /><sentence text="3%" /><sentence text=" Whereas, moderate- and major-pDDIs were found in 377 (15" /><sentence text="7%) and 225 (9" /><sentence text="4%), respectively" /><sentence text=" PDDIs were more prevalent in Medicine (9" /><sentence text="2%) and Cardiology (2" /><sentence text="6%) as compared with other OPD specialties" /><sentence text=" Total 942 pDDIs were identified, of which, the majority were either moderate- (61" /><sentence text="9%) or major-pDDIs (32" /><sentence text="1%)" /><sentence text=" Some of the most common interactions were ibuprofen + levofloxacin (n = 50), ciprofloxacin + diclofenac (32), aspirin + atenolol (24), and diclofenac + levofloxacin (19)"><entity charOffset="43-67" id="DDI-PubMed.30314487.s21.e0" text="ibuprofen + levofloxacin" /><entity charOffset="78-104" id="DDI-PubMed.30314487.s21.e1" text="ciprofloxacin + diclofenac" /><entity charOffset="111-118" id="DDI-PubMed.30314487.s21.e2" text="aspirin" /><entity charOffset="140-165" id="DDI-PubMed.30314487.s21.e3" text="diclofenac + levofloxacin" /><pair ddi="false" e1="DDI-PubMed.30314487.s21.e0" e2="DDI-PubMed.30314487.s21.e0" /><pair ddi="false" e1="DDI-PubMed.30314487.s21.e0" e2="DDI-PubMed.30314487.s21.e1" /><pair ddi="false" e1="DDI-PubMed.30314487.s21.e0" e2="DDI-PubMed.30314487.s21.e2" /><pair ddi="false" e1="DDI-PubMed.30314487.s21.e0" e2="DDI-PubMed.30314487.s21.e3" /><pair ddi="false" e1="DDI-PubMed.30314487.s21.e1" e2="DDI-PubMed.30314487.s21.e1" /><pair ddi="false" e1="DDI-PubMed.30314487.s21.e1" e2="DDI-PubMed.30314487.s21.e2" /><pair ddi="false" e1="DDI-PubMed.30314487.s21.e1" e2="DDI-PubMed.30314487.s21.e3" /><pair ddi="false" e1="DDI-PubMed.30314487.s21.e2" e2="DDI-PubMed.30314487.s21.e2" /><pair ddi="false" e1="DDI-PubMed.30314487.s21.e2" e2="DDI-PubMed.30314487.s21.e3" /></sentence><sentence text=" The potential adverse outcomes of widespread interactions were seizures, bleeding, QT-interval prolongation, arrhythmias, tendon rupture, hypoglycemia/hyperglycemia, serotonin syndrome, drug toxicity, and decreased therapeutic response"><entity charOffset="167-176" id="DDI-PubMed.30314487.s22.e0" text="serotonin" /></sentence><sentence text="" /><sentence text="OPD patients were at risk to pDDIs, particularly to major- and moderate-pDDIs" /><sentence text=" Screening of prescriptions for pDDIs and monitoring of pharmacotherapy in terms of response and associated adverse drug events will contribute to patient safety" /><sentence text="" /></document>